As clinical trials become more complex, success depends on early collaboration, thoughtful protocol design, and practical ...

Company opts not to advance VX-993 into pivotal development after Phase II data show no statistically significant benefit ...

In this video interview, Luke Wilson, senior director, biotech, pharma services at Thermo Fisher Scientific, explains how ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...